Several previous studies have reported prolongation of the survival time in patients with EGFR-mutation-positive lung carcinomas treated with EGFR-tyrosine kinase inhibitors (TKIs) [8-11], therefore, EGFR-TKIs are widely used in medical practice. The gene discussed is EGFR; the disease is lung carcinoma.